Uro-oncology · KIMS Secunderabad
Non-Muscle Invasive Bladder Cancer — Diagnosis, TUR-BT, and Keeping It from Recurring
Bladder cancer is classified primarily by how deeply the tumour has invaded the bladder wall. Non-muscle invasive bladder cancer (NMIBC) — also called superficial bladder cancer — is confined to the inner lining of the bladder (urothelium) and the connective tissue layer immediately beneath it (lamina propria), without invading the thick muscle layer (detrusor muscle) of the bladder wall. Approximately 75 to 80% of newly diagnosed bladder cancers are NMIBC — making it by far the more common presentation. The good news: NMIBC is highly treatable, with cure rates above 90% for low-grade disease. The challenge: NMIBC has a very high recurrence rate, and a proportion of tumours progress to muscle-invasive bladder cancer if surveillance is inadequate.
Management of NMIBC at KIMS follows the EAU (European Association of Urology) risk stratification guidelines: transurethral resection of the bladder tumour (TUR-BT) to diagnose, stage, and treat simultaneously, followed by intravesical therapy (BCG or mitomycin C) and lifelong cystoscopy surveillance to detect recurrence early.
Classification and risk stratification
Low risk — pTa low-grade
Non-invasive papillary tumour, low malignant potential. Recurrence 50–70% at 5 years · Progression below 5%. Treatment: TUR-BT + single immediate post-operative intravesical mitomycin C instillation. Surveillance: Cystoscopy at 3 months then annually if disease-free.
Intermediate risk — pTa high-grade or pT1 low-grade
Invasion of lamina propria or high-grade non-invasive disease. Recurrence 60–80% · Progression 15–20%. Treatment: TUR-BT (± re-resection at 4–6 weeks for pT1) + induction BCG × 6 weekly instillations + maintenance BCG. Surveillance: Cystoscopy every 3 months for 2 years.
High risk — pT1 high-grade or carcinoma in situ (CIS)
High-grade lamina propria invasion or flat high-grade lesion. Recurrence above 80% · Progression 30–50%. Treatment: TUR-BT + re-resection at 4–6 weeks (mandatory for pT1 HG) + induction + maintenance BCG for 1–3 years. Surveillance: Cystoscopy every 3 months for 2 years, then 6-monthly · Cystectomy if BCG-refractory.
Transurethral resection of bladder tumour (TUR-BT)
TUR-BT is the cornerstone of NMIBC management — it is simultaneously the diagnostic procedure (obtaining tissue for histopathological staging and grading), the staging procedure (determining depth of invasion), and the initial treatment (removing the visible tumour). Performed under spinal or general anaesthesia through a cystoscope:
All visible tumours are resected completely — including the base of the tumour (to assess whether the detrusor muscle has been invaded). A tumour resection that does not include muscle in the specimen is inadequate — it cannot stage the tumour and re-resection is required.
Single immediate post-operative intravesical mitomycin C (40mg in 40ml saline) within 24 hours of TUR-BT — reduces the risk of tumour cell implantation and significantly reduces recurrence rates in low-risk tumours. Contraindicated if there is bladder perforation.
Re-resection (second TUR-BT) at 4 to 6 weeks — mandatory for all pT1 tumours (to exclude understaging to muscle-invasive disease) and for any pTa/pT1 tumour where the initial resection was incomplete or did not include detrusor muscle in the specimen. At KIMS, re-resection is performed as a matter of protocol for all pT1 high-grade tumours.
BCG immunotherapy — the primary adjuvant treatment
Bacillus Calmette-Guérin (BCG) is an attenuated Mycobacterium bovis instilled directly into the bladder through a urethral catheter. BCG induces a local immune response within the bladder urothelium that destroys residual tumour cells and — critically — prevents recurrence and progression. BCG is the most effective intravesical agent for intermediate and high-risk NMIBC.
Induction course
6 weekly instillations, each retained in the bladder for 2 hours. Performed in the KIMS urology outpatient clinic.
Maintenance BCG (SWOG schedule)
3 weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months (the SWOG full maintenance schedule) significantly reduces recurrence and progression compared to induction alone. Maintenance BCG for at least 1 year is recommended for intermediate-risk; 1 to 3 years for high-risk NMIBC.
BCG side effects and precautions
Most commonly dysuria, frequency, and haematuria for 24 to 48 hours after instillation. Systemic BCG sepsis (rare — below 1%) requires urgent hospitalisation and anti-TB therapy (rifampicin + isoniazid). BCG is withheld for 2 weeks after TUR-BT, traumatic catheterisation, or active UTI.
Surveillance cystoscopy — the lifelong commitment
NMIBC has one of the highest recurrence rates of any cancer — 50 to 80% of patients develop a recurrence within 5 years. The recurrences are usually at the same stage or lower — but 15 to 30% progress to muscle-invasive disease if missed. This is why lifelong cystoscopy surveillance is non-negotiable. At KIMS, every NMIBC patient is enrolled in a structured surveillance programme with cystoscopy every 3 months for 2 years (for intermediate and high-risk), then 6-monthly, then annually indefinitely.
Book a Bladder Cancer Consultation at KIMS — TUR-BT and BCG Programme
Frequently Asked Questions — Non-Muscle Invasive Bladder Cancer
Non-muscle invasive bladder cancer (NMIBC) is confined to the inner lining of the bladder — the urothelium (pTa) and the connective tissue layer beneath it (lamina propria — pT1). It has not penetrated the thick muscle wall (detrusor muscle) of the bladder. Muscle-invasive bladder cancer (MIBC — pT2 and above) has grown through the urothelium and lamina propria into the detrusor muscle and beyond. This distinction is the single most important prognostic and treatment decision: NMIBC is managed endoscopically (TUR-BT + BCG), while MIBC requires radical surgery (radical cystectomy — removal of the entire bladder) or definitive chemoradiation. The TUR-BT specimen must include detrusor muscle to make this staging distinction reliably.
Low-grade NMIBC (pTa) has very low metastatic potential — it rarely spreads beyond the bladder. High-grade pT1 disease has a higher risk of harbouring occult muscle invasion (understaging) and metastatic risk — which is why re-resection is mandatory for pT1 high-grade tumours. If the pT1 tumour turns out on re-resection to be muscle-invasive, the staging changes to MIBC and radical cystectomy becomes the recommended treatment. The purpose of the rigorous TUR-BT and re-resection protocol at KIMS is precisely to avoid understaging a muscle-invasive tumour as NMIBC.
Both — BCG (Bacillus Calmette-Guérin) is the same organism used in the TB vaccine (BCG), but when instilled into the bladder in patients with NMIBC it acts as an immunotherapy rather than a vaccine. The bacterial antigens trigger a local immune response within the bladder wall — recruiting immune cells that attack and destroy residual tumour cells and prevent new tumour implantation. BCG is the most effective intravesical agent for preventing NMIBC recurrence and progression and has been used for bladder cancer treatment since the 1970s. It is not administered systemically — it is instilled directly into the bladder and retained for 2 hours, then voided.
For intermediate and high-risk NMIBC: cystoscopy every 3 months for the first 2 years after TUR-BT, then every 6 months for years 3 and 4, then annually indefinitely. For low-risk NMIBC: cystoscopy at 3 months after TUR-BT — if disease-free, annual cystoscopy. KIMS enrolls every NMIBC patient in a structured surveillance calendar. Urine cytology is performed at each surveillance cystoscopy for high-grade tumours — cytology is sensitive for detecting high-grade recurrence and CIS even when the bladder appears visually normal at cystoscopy. Surveillance is lifelong — missing a cystoscopy or abandoning surveillance because 'nothing has been found for a few years' allows a recurrence to progress unseen.
BCG failure — defined as high-risk NMIBC persisting or recurring within 6 months of adequate BCG therapy — carries a high risk of progression to muscle-invasive disease. In this situation, radical cystectomy (removal of the entire bladder) is the recommended treatment at KIMS — the cancer has demonstrated that it cannot be controlled endoscopically. Delay of cystectomy in BCG-refractory high-risk NMIBC significantly worsens oncological outcomes. Alternatives for patients not fit for cystectomy: pembrolizumab (PD-1 inhibitor — approved for BCG-unresponsive CIS in several countries, increasingly available in India), intravesical gemcitabine plus docetaxel, or nadofaragene firadenovec (gene therapy — emerging). The KIMS MDT tumour board reviews every BCG-refractory case.
KIMS Secunderabad — Dr. Likhiteswer Pallagani (Vattikuti Foundation uro-oncology fellowship, 400+ robotic cases, MDT tumour board), TUR-BT with mandatory muscle sampling, immediate post-operative mitomycin C protocol, BCG induction and maintenance programme, structured 3-monthly cystoscopy surveillance, re-resection protocol for pT1 high-grade, robotic radical cystectomy (RARC) for BCG-refractory or muscle-invasive disease. NABH and NABL accredited. Call 040-4488-5000.